{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:24Z","timestamp":1790727084432,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recently, tumor immunotherapy based on immune checkpoint inhibitors (ICI) has been introduced and widely adopted for various tumor types. Nevertheless, tumor immunotherapy has a few drawbacks, including significant uncertainty of outcome, the possibility of severe immune-related adverse events for patients receiving such treatments, and the lack of effective biomarkers to determine the ICI treatments\u2019 responsiveness. DNA methylation profiles were recently identified as an indicator of the tumor immune microenvironment. They serve as a potential hot spot for predicting responses to ICI treatment for their stability and convenience of measurement by liquid biopsy. We demonstrated the possibility of DNA methylation profiles as a predictor for responses to the ICI treatments at the pan-cancer level by analyzing DNA methylation profiles considered responsive and non-responsive to the treatments. An SVM model was built based on this differential analysis in the pan-cancer levels. The performance of the model was then assessed both at the pan-cancer level and in specific tumor types. It was also compared to the existing gene expression profile-based method. DNA methylation profiles were shown to be predictable for the responses to the ICI treatments in the TCGA cases in pan-cancer levels. The proposed SVM model was shown to have high performance in pan-cancer and specific cancer types. This performance was comparable to that of gene expression profile-based one. The combination of the two models had even higher performance, indicating the potential complementarity of the DNA methylation and gene expression profiles in the prediction of ICI treatment responses.<\/jats:p>","DOI":"10.3389\/fimmu.2021.796647","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T05:28:55Z","timestamp":1639027735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Bingxiang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A Decade of Immune-Checkpoint Inhibitors in Cancer Therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/d41573-019-00167-9","article-title":"Immuno-Oncology Drug Development Goes Global","volume":"18","author":"Jia","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma Without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-Related Adverse Events of Checkpoint Inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00673","article-title":"Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1\/PD-L1 Inhibitions: A Meta-Analysis","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal Neoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune Checkpoint Blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-019-0787-5","article-title":"Tumor Neoantigens: From Basic Research to Clinical Applications","volume":"12","author":"Jiang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-019-0177-8","article-title":"Immune Biomarkers in Thymic Epithelial Tumors: Expression Patterns, Prognostic Value and Comparison of Diagnostic Tests for PD-L1","volume":"7","author":"Rouquette","year":"2019","journal-title":"Biomark Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of Cancer Immunity and the Cancer-Immune Set Point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.Cd-14-0863","article-title":"The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","article-title":"DNA Methylation Loss Promotes Immune Evasion of Tumours With High Mutation and Copy Number Load","volume":"10","author":"Jung","year":"2019","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.05.019","article-title":"The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective From the International Association for the Study of Lung Cancer Pathology Committee","volume":"15","author":"Sholl","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMc1510353","article-title":"PD-1 Blockade in Tumors With Mismatch-Repair Deficiency","volume":"373","author":"Asaoka","year":"2015","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1038\/s41598-020-59690-0","article-title":"Crosstalk Between DNA Methylation and Gene Expression in Colorectal Cancer, a Potential Plasma Biomarker for Tracing This Tumor","volume":"10","author":"Kerachian","year":"2020","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-721-1_9","article-title":"Determining the Effect of DNA Methylation on Gene Expression in Cancer Cells","volume":"1101","author":"Lee","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/00000658-200107000-00003","article-title":"DNA Methylation: An Alternative Pathway to Cancer","volume":"234","author":"Wajed","year":"2001","journal-title":"Ann Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/b978-0-12-380866-0.60002-2","article-title":"DNA Methylation and Cancer","volume":"70","author":"Kulis","year":"2010","journal-title":"Adv Genet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the Epigenetic Regulation of Antitumour Immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3799","article-title":"Genome-Wide DNA-Methylation Landscape Defines Specialization of Regulatory T Cells in Tissues","volume":"18","author":"Delacher","year":"2017","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1038\/s41467-018-05570-1","article-title":"Pan-Cancer Deconvolution of Tumour Composition Using DNA Methylation","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.08.02","article-title":"Methods of Measurement for Tumor Mutational Burden in Tumor Tissue","volume":"7","author":"Mel\u00e9ndez","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17546","DOI":"10.1038\/s41598-018-35682-z","article-title":"MSIpred: A Python Package for Tumor Microsatellite Instability Classification From Tumor Mutation Annotation Data Using a Support Vector Machine","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-604","article-title":"Improved Prognostic Classification of Breast Cancer Defined by Antagonistic Activation Patterns of Immune Response Pathway Modules","volume":"10","author":"Teschendorff","year":"2010","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic Signaling Pathways in the Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"Tgf\u03b2 Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12865-018-0285-5","article-title":"Correlate Tumor Mutation Burden With Immune Signatures in Human Cancers","volume":"20","author":"Wang","year":"2019","journal-title":"BMC Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-Cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.07.010","article-title":"Biomarkers of Response to Immune Checkpoint Blockade in Cancer Treatment","volume":"130","author":"Fujii","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41598-017-01000-2","article-title":"Indicators of Responsiveness to Immune Checkpoint Inhibitors","volume":"7","author":"Shields","year":"2017","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/cancers11101562","article-title":"A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning","volume":"11","author":"Polano","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00493-8","article-title":"Genome-Wide Identification of Differentially Methylated Promoters and Enhancers Associated With Response to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer","volume":"52","author":"Cho","year":"2020","journal-title":"Exp Mol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With Deseq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v061.i06","article-title":"NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set","volume":"61","author":"Malika","year":"2014","journal-title":"J Stat Software"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eswa.2016.12.035","article-title":"Learning From Class-Imbalanced Data: Review of Methods and Applications","volume":"73","author":"Guo","year":"2017","journal-title":"Expert Syst Appl"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.3390\/molecules24152811","article-title":"Multi-Level Comparison of Machine Learning Classifiers and Their Performance Metrics","volume":"24","author":"R\u00e1cz","year":"2019","journal-title":"Molecules"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2006.050092","article-title":"Comparison of the Microsatellite Instability Analysis System and the Bethesda Panel for the Determination of Microsatellite Instability in Colorectal Cancers","volume":"8","author":"Murphy","year":"2006","journal-title":"J Mol Diagn"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2174\/156800961506150805145120","article-title":"Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety","volume":"15","author":"Azoury","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz049","article-title":"Machine Learning-Based Predictors for Immune Checkpoint Inhibitor Therapy of Non-Small-Cell Lung Cancer","volume":"30","author":"Wiesweg","year":"2019","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"eaay6298","DOI":"10.1126\/sciadv.aay6298","article-title":"Mathematical Prediction of Clinical Outcomes in Advanced Cancer Patients Treated With Checkpoint Inhibitor Immunotherapy","volume":"6","author":"Butner","year":"2020","journal-title":"Sci Adv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00905","article-title":"Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.104523","article-title":"Response Rates and Survival to Systemic Therapy After Immune Checkpoint Inhibitor Failure in Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma","volume":"101","author":"Pestana","year":"2020","journal-title":"Oral Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.3390\/cancers11111741","article-title":"Cell-Free Dna Methylation Profiling Analysis-Technologies and Bioinformatics","volume":"11","author":"Huang","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-612-8_23","article-title":"Dietary and Lifestyle Factors of DNA Methylation","volume":"863","author":"Lim","year":"2012","journal-title":"Methods Mol Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0547-7","article-title":"Minimalist Approaches to Cancer Tissue-of-Origin Classification by DNA Methylation","volume":"33","author":"Xia","year":"2020","journal-title":"Mod Pathol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/jcm9010286","article-title":"Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response","volume":"9","author":"Xiao","year":"2020","journal-title":"J Clin Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.796647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T05:29:03Z","timestamp":1639027743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.796647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2021.796647"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.796647","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,9]]},"article-number":"796647"}}